| Old Articles: <Older 2711-2720 Newer> |
|---|
 |
Bio-IT World
February 2006
G. Steven Burrill |
Outlook for '06, Look Back at '05 Overall, 2005 turned out to be an exceptional year for the biotech industry, but it wasn't all good news: Look Back at 2005... Predictions for 2006...   |
Bio-IT World
February 2006
Chris Connor |
Has EDC Jumped the Shark? As data management teams begin to deploy electronic data capture in their clinical trials, "cool" gives way to the cool reality that IT investments have to produce real results. |
Bio-IT World
February 2006 |
News Blast Trimming at Tripos... RNAi Settlement... Personalized Push... |
Bio-IT World
February 2006
John Russell |
Inside BG Medicine Think Intel Inside, but instead of microprocessors, think industrial-strength experimental platforms, focused on all things omic, designed and even run by a third party, but living deep inside biopharmaceutical companies. This is BM Medicine's CEO Pieter Muntendam's strategy. |
Bio-IT World
February 2006
Mark D. Uehling |
Pharma's Mixed Response to Trials Database A late December New England Journal of Medicine article detailed Big Pharma's response to mandatory registration of clinical trials. Here are some highlights. |
Bio-IT World
February 2006
Kevin Davies |
Solexa Readies 1G Genetic Analyzer Solexa, one of the firms vying to crack the $1,000 genome threshold, has officially launched its first commercial genome sequencing instrument. |
Bio-IT World
February 2006 |
News Blast Hit-to-Lead... Whole Genome... Gleevec Resistance... |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
BusinessWeek
March 6, 2006
Bruce Einhorn |
A Cancer Treatment You Can't Get Here China, with lower regulatory hurdles, is racing to a lead in gene therapy. |
The Motley Fool
February 22, 2006
Stephen D. Simpson |
Axcan Kicked in the Guts The failure of a phase 3 trial puts future growth prospects for Canadian specialty pharmaceutical AxcanPharma in doubt. Investors, take note. |
| <Older 2711-2720 Newer> Return to current articles. |
